| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A770 | Mezagitamab Featured | Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP). |
|
| A771 | Foralumab Featured | Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells. |
|
| A772 | Teplizumab Featured | Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. |
|
| A773 | Ibalizumab Featured | Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. |
|
| A774 | Tregalizumab Featured | Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies. |
|
| A775 | Anti-CD4 Antibody (TRX1) Featured |
|
|
| A776 | Bivatuzumab Featured | Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells. |
|
| A777 | FG-3246 (FOR46) Featured |
|
|
| A778 | Letaplimab Featured | Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis. |
|
| A779 | CC-90002 Featured | CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors. |
|
| A780 | Ligufalimab Featured | Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity. |
|
| A781 | Lemzoparlimab Featured | Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity. |
|
| A782 | Magrolimab Featured | Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer. |
|
| A783 | Urabrelimab Featured | Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction. |
|
| A784 | Regeneron patent anti-CD48 Featured |
|
|
| A785 | Magenta patent anti-CD5 Featured |
|
|
| A786 | Gatralimab Featured | Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody. |
|
| A787 | Mellitus patent anti-CD59 Featured |
|
|
| A788 | Quark patent anti-CD59 Featured |
|
|
| A789 | Itolizumab Featured | Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19. |
|
| A790 | Grisnilimab Featured | Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA. |
|
| A791 | Persongen patent anti-CD7 Featured |
|
|
| A792 | MilatuzuMab Featured | Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. |
|
| A793 | Iladatuzumab Featured | Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
| A794 | Polatuzumab Featured | Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b . |
|
| A795 | Genentech patent anti-CD83 Featured |
|
|
| A796 | Genentech patent anti-CD9 Featured |
|
|
| A797 | DCBY02 Featured |
|
|
| A798 | Ign523 Featured |
|
|
| A799 | Anti-CDCP1/CD318 Antibody (38 E11) Featured |
|
